WebNov 12, 2015 · PINE BROOK, N.J., Nov. 12, 2015 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim ... WebANTHIM is a clear to opalescent, colorless to pale yellow to pale brownish-yellow solution and may contain few translucent-to-white proteinaceous particulates. Elusys has received funding for ANTHIM from the U.S. Department of Defense (DoD), National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).
Zacks Small Cap Research - NHWK: ANTHIM Sales Boost …
WebANTHIM® (oblitoxaximab) is a Medical Countermeasure to Mitigate the Effect of Anthrax Exposure. Elusys has been awarded over $400 million in procurement and development … WebIn April 2024, Heat Biologics, Inc. announced the completion of its acquisition of Elusys Therapeutics, Inc., a commercial-stage biodefense firm and developer of the anthrax therapy ANTHIM (obiltoxaximab). ANTHIM is approved for use in the United States and Canada, as well as in Europe and the United Kingdom, under the brand name Obiltoxaximab SFL. pentair wfe-3 011512
2024-01-31 - Elusys
WebAnthim was developed by Elusys Therapeutics, Inc. of Pine Brook, New Jersey, in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development ... WebApr 27, 2024 · New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawk. DURHAM, N.C., April 27, 2024 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on developing first … WebApr 11, 2024 · Elusys has been supplying Anthim to the US Strategic National Stockpile through an ongoing, multi-year partnership. Anthim is a monoclonal antibody that binds … todd crill auctions creston ia